Moxigreat 0.5% Ophthalmic Solution

Introduction

Moxigreat is a prescription medication that contains the active ingredient Moxifloxacin. It is available in the form of eye drops and is commonly used to treat bacterial infections of the eyes.

Uses

Moxigreat is prescribed for the treatment of bacterial conjunctivitis, also known as pink eye. This condition is characterized by redness, itching, and discharge from the eyes caused by a bacterial infection.

Dosage and Administration

The recommended dosage of Moxigreat is usually one drop in the affected eye(s) every 4 to 6 hours for up to 7 days. Follow the instructions provided by your healthcare professional regarding the duration of treatment and the frequency of administration.

To administer the eye drops, wash your hands thoroughly and tilt your head back slightly. Gently pull down the lower eyelid to create a small pocket. Hold the dropper close to your eye and squeeze the prescribed number of drops into the pocket. After applying the drops, close your eyes for a minute to allow the medication to spread evenly over the surface of the eye. Avoid touching the dropper tip to any surface to prevent contamination.

Mechanism of Action

Moxifloxacin, the active ingredient in Moxigreat, belongs to a class of medications called fluoroquinolone antibiotics. It works by inhibiting the growth of bacteria, preventing them from multiplying and causing further infection. This helps to reduce the symptoms of bacterial conjunctivitis and promote healing.

Side Effects

Common side effects may include stinging or burning sensation in the eyes, temporary blurred vision, eye irritation, or dryness. These side effects are usually mild and should resolve on their own.

However, if you experience any serious side effects such as severe eye pain, swelling, redness, or vision changes, seek medical attention immediately.

Drug Interactions

Before using Moxigreat, inform your healthcare professional about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Certain medications may interact with moxifloxacin and affect its effectiveness or increase the risk of side effects. Consult with your healthcare professional to ensure there are no potential drug interactions.

Precautions

There are certain precautions that should be taken into consideration when using Moxigreat. Inform your healthcare professional if you have any known allergies or sensitivities to moxifloxacin or other fluoroquinolone antibiotics.

Additionally, avoid touching the tip of the dropper to any surface, including the eyes, to prevent contamination. Do not wear contact lenses while using Moxigreat unless specifically instructed by your healthcare professional.

If you are pregnant, planning to become pregnant, or breastfeeding, discuss the potential risks and benefits of using this medication with your healthcare professional.

Storage

Patient Tips

• Wash your hands before and after using Moxigreat to prevent the spread of infection.
• If you are using other eye medications, wait at least 5 minutes before applying Moxigreat to allow the previous medication to be absorbed.
• If you experience any discomfort or irritation after applying the eye drops, consult your healthcare professional.
• Do not share your medication with others, even if they have similar symptoms.
• If your symptoms do not improve or worsen after a few days of treatment, contact your healthcare professional for further evaluation.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Avelox 400 mg film-coated tablets (Health Professionals SmPC) Available at:
• Moxifloxacin oral/injection (Drugs.com) [Accessed 14 Jun. 2024] (online) Available at:
• moxifloxacin drops (RX) [Accessed 10 Jun. 2024] (online) Available at:
• Moxifloxacin (MedlinePlus) [Accessed 6 Jun. 2024] (online) Available at:
• Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. [Accessed 12 Jun. 2024] Available at: